Switch to:

Intra-Cellular Therapies EV-to-EBITDA

: -8.25 (As of Today)
View and export this data going back to 2013. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intra-Cellular Therapies's enterprise value is $1,580.64 Mil. Intra-Cellular Therapies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-191.55 Mil. Therefore, Intra-Cellular Therapies's EV-to-EBITDA for today is -8.25.

NAS:ITCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4   Med: -6   Max: -0.2
Current: -8.25

-31.4
-0.2

During the past 8 years, the highest EV-to-EBITDA of Intra-Cellular Therapies was -0.20. The lowest was -31.40. And the median was -6.00.

NAS:ITCI's EV-to-EBITDA is ranked lower than
99.99% of the 268 Companies
in the Biotechnology industry.

( Industry Median: 29.59 vs. NAS:ITCI: -8.25 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2020-10-27), Intra-Cellular Therapies's stock price is $24.86. Intra-Cellular Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was $-3.06. Therefore, Intra-Cellular Therapies's PE Ratio for today is .

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Intra-Cellular Therapies EV-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Intra-Cellular Therapies Annual Data
Dec12 Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only -17.59 -2.31 -3.18 -1.72 -11.10

Intra-Cellular Therapies Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.81 -1.16 -11.10 -3.46 0.00

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Intra-Cellular Therapies EV-to-EBITDA Distribution

* The bar in red indicates where Intra-Cellular Therapies's EV-to-EBITDA falls into.



Intra-Cellular Therapies EV-to-EBITDA Calculation

Intra-Cellular Therapies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1580.636/-191.551
=-8.25

Intra-Cellular Therapies's current Enterprise Value is $1,580.64 Mil.
Intra-Cellular Therapies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was -36.247 (Sep. 2019 ) + -41.627 (Dec. 2019 ) + -48.937 (Mar. 2020 ) + -64.74 (Jun. 2020 ) = $-191.55 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Intra-Cellular Therapies  (NAS:ITCI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Intra-Cellular Therapies's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=24.86/-3.06
=

Intra-Cellular Therapies's share price for today is $24.86.
Intra-Cellular Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was -0.63 (Sep. 2019 ) + -0.74 (Dec. 2019 ) + -0.73 (Mar. 2020 ) + -0.96 (Jun. 2020 ) = $-3.06.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Intra-Cellular Therapies EV-to-EBITDA Related Terms


Intra-Cellular Therapies EV-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)